South Korea-based AMI Pharm announced on Monday that its novel injectable drug, AYP-101, has shown promising results in a Phase 2 clinical trial for the reduction of submental fat (SMF), commonly known as a double chin.

Clinical data from the trial was recently published in Clinical Therapeutics, a journal for drug and therapy development, highlighting its potential as a safe and effective non-surgical treatment option.

The study evaluated the efficacy and safety of AYP-101 at two different concentrations. Results showed that the 25 mg/mL concentration, administered every two weeks for six sessions, led to statistically significant and clinically meaningful reductions in moderate to severe SMF.

According to AMI Pharm, the Phase 2 study enrolled 96 participants and demonstrated strong results. With the global demand for non-surgical fat reduction solutions on the rise, AMI Pharm is actively pursuing the next phase of development. According to Ki-Taek Lee, AMI Pharm CEO, the publication of the Phase 2 data reaffirms the company's research capabilities and demonstrates AYP-101's significant potential in the localised fat reduction market.